Loading
A phase 3 trial of Cabozantinib, Atezolizumab, Abiraterone acetate in prostate cancer, run by Exelixis, active and no longer recruiting.
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC is a phase 3 interventional study registered as NCT04446117 by Exelixis, with 575 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2024-04-19. Interventions recorded: Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone. Conditions listed: Metastatic Prostate Cancer, Prostate Adenocarcinoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
575 enrolled.
95% CI 6.18 to 8.80; Figures from the ClinicalTrials.gov results section (first posted 2025-12-18), not from a publication · 95% CI 3.71 to 5.65
Source95% CI 13.37 to 16.66; Figures from the ClinicalTrials.gov results section (first posted 2025-12-18), not from a publication · 95% CI 13.01 to 18.50
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)primary | Experimental Arm: Cabozantinib and Atezolizumab | 200 | 6.34 months | - | 0.0007 | link |
| Control Arm: Second NHT | 200 | 4.17 months | ||||
| Duration of Overall Survival (OS)primary | Experimental Arm: Cabozantinib and Atezolizumab | 289 | 14.78 months | - | 0.2956 | link |
| Control Arm: Second NHT | 286 | 14.98 months |
Shares Exelixis, Cabozantinib, Abiraterone acetate, Enzalutamide.
Shares Exelixis, Cabozantinib, Atezolizumab, Anti-angiogenic therapy.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Cabozantinib, Atezolizumab, Immune checkpoint inhibitors.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Cabozantinib, Prednisone, Metastatic castration-resistant prostate cancer.
Shares Abiraterone acetate, Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.